Why Natera (NTRA) Is Up 6.3% After New Signatera Cancer Trial And Japan Launch Milestones
Natera, Inc. recently announced a series of collaborations and product advances, including integrating its Signatera MRD test into Aveta Biomics’ global Phase 3 head and neck cancer trial, expanding Prospera’s role in kidney transplant ...